Chronic myelomonocytic leukemia: from biology to therapy.

[1]  G. Mufti,et al.  Possible co-existence of RAS activation and monosomy 7 in the leukaemic transformation of myelodysplastic syndromes. , 1995, Leukemia research.

[2]  C. Preudhomme,et al.  Prognostic value of c-mpl expression in myelodysplastic syndromes. , 1995, Leukemia.

[3]  U. Germing,et al.  Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. , 1994, Leukemia.

[4]  P. Fenaux,et al.  Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. , 1994, Leukemia.

[5]  B. Quesnel,et al.  Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes , 1994, British journal of haematology.

[6]  C. Denny,et al.  Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about , 1994, Cell.

[7]  P. O'Connell,et al.  Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. , 1994, The New England journal of medicine.

[8]  N. Iscove,et al.  Overexpression of PDGF-B in murine hematopoietic cells induces a lethal myeloproliferative syndrome in vivo. , 1994, Oncogene.

[9]  N. Gattermann,et al.  All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. , 1993, Blood.

[10]  J. Guénet,et al.  Characterization of the murine Mpl proto-oncogene, a member of the hematopoietic cytokine receptor family: molecular cloning, chromosomal location and evidence for a function in cell growth. , 1993, Oncogene.

[11]  E. Estey,et al.  All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. McCormick,et al.  N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. , 1993, Blood.

[13]  P. Sonneveld,et al.  High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. , 1993, Leukemia.

[14]  G. Mufti,et al.  Myelodysplastic syndromes: from morphology to molecular biology. Part II. The molecular genetics of myelodysplasia. , 1993, International journal of hematology.

[15]  J. Rowley,et al.  Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion , 1993 .

[16]  T. Naoe,et al.  Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. , 1993, Blood.

[17]  P. Martiat,et al.  Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome? , 1993, Leukemia & lymphoma.

[18]  W. Fibbe,et al.  t(5;12)(q31;p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia. , 1993, Cancer genetics and cytogenetics.

[19]  I. Pannacciulli,et al.  MYELODYSPLASTIC SYNDROME ASSOCIATED WITH INCREASED BONE MARROW FIBROSIS AND TRANSLOCATION (5;12)(q33:p12·3) , 1992, British journal of haematology.

[20]  R. Warrell,et al.  The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia , 1992, Annals of Internal Medicine.

[21]  S. Pileri,et al.  Overexpression of multidrug resistance‐associated p170‐glycoprotein in acute non‐lymphocytic leukemia , 1992, European journal of haematology.

[22]  M. Mangi,et al.  Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. , 1992, Blood.

[23]  R. Berger,et al.  Mutations in the p53 gene in myelodysplastic syndromes. , 1991, Oncogene.

[24]  P. Shaw,et al.  Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. , 1991, Oncogene.

[25]  R. Berger,et al.  P53 gene mutations in acute myeloid leukemia with 17p monosomy. , 1991, Blood.

[26]  M. Minden,et al.  Mutation of the p53 gene in human acute myelogenous leukemia. , 1991, Blood.

[27]  P. Morel,et al.  Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy , 1991, British journal of haematology.

[28]  Y. Neuman,et al.  Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12). A new association. , 1991, Cancer genetics and cytogenetics.

[29]  P. O’Connell,et al.  The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21 , 1990, Cell.

[30]  P. Fenaux,et al.  All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. , 1990, Blood.

[31]  C. T. Davis,et al.  Minimal subenhancer requirements for high-level polyomavirus DNA replication: a cell-specific synergy of PEA3 and PEA1 sites , 1990, Molecular and cellular biology.

[32]  C. March,et al.  A new cytokine receptor superfamily. , 1990, Trends in biochemical sciences.

[33]  A. Kitzis,et al.  Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease , 1990, British journal of haematology.

[34]  J. Goasguen,et al.  Prognostic factors of myelodysplastic syndromes--a simplified 3-D scoring system. , 1990, Leukemia research.

[35]  M. Lavin,et al.  Cell death by apoptosis in acute leukaemia , 1989, The Journal of pathology.

[36]  Yunis Jj,et al.  Mechanisms of ras mutation in myelodysplastic syndrome. , 1989 .

[37]  E. Montserrat,et al.  Acute transformation of chronic myelomonocytic leukaemia: a multivariate study of predictive factors , 1989, European journal of haematology.

[38]  N. Heerema,et al.  KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. , 1988, Cancer genetics and cytogenetics.

[39]  F. McCormick,et al.  RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. , 1988, Leukemia.

[40]  G. Mufti,et al.  Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. , 1988, Blood.

[41]  F. Grant,et al.  Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: evidence for more than one receptor class. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Saiki,et al.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Heitjan,et al.  Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. , 1988, Blood.

[44]  C. Bartram,et al.  RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W. Wilmanns,et al.  Mechanisms and prognostic value of cell kinetics in the myelodysplastic syndromes , 1987, British journal of haematology.

[46]  V. Broudy,et al.  Cytogenetic evidence for involvement of B lymphocytes in acquired idiopathic sideroblastic anemias. , 1987, Blood.

[47]  Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML). , 1987, British Journal of Cancer.

[48]  P. Fenaux,et al.  Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors , 1987, British journal of haematology.

[49]  J. Hermans,et al.  Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases , 1987, British journal of haematology.

[50]  R. Simon,et al.  A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Galton Da,et al.  Myelodysplastic syndromes: natural history and features of prognostic importance. , 1986, Clinics in haematology.

[52]  J. Griffin,et al.  Autocrine secretion of GM-CSF in acute myeloblastic leukemia. , 1986, Blood.

[53]  A. Ullrich,et al.  Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors , 1986, Nature.

[54]  G. Mufti,et al.  Immunological abnormalities in myelodysplastic syndromes I. SERUM IMMUNOGLOBULINS AND AUTOANTIBODIES , 1986, British journal of haematology.

[55]  Chronic myelomonocytic leukemia: Clinical features, cytogenetics, and prognosis in 30 consecutive cases , 1985, Hematological oncology.

[56]  V. Rotter,et al.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation , 1984, Nature.

[57]  P. Fialkow,et al.  Evidence for a multistep pathogenesis of a myelodysplastic syndrome. , 1984, Blood.

[58]  P. Seeburg,et al.  Tripartite structure of the avian erythroblastosis virus E26 transforming gene , 1983, Nature.

[59]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[60]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.